Information Provided By:
Fly News Breaks for October 5, 2016
EW
Oct 5, 2016 | 08:51 EDT
JPMorgan analyst Michael Weinstein raised his price target for Edwards Lifesciences to $135 saying his firm's fourth survey this year of cardiologists and surgeons indicate the TAVR market is accelerating. The analyst raised his TAVR market estimates to $5.1B in 2020, up from $4.7B, and keeps an Overweight rating on Edwards.